Progress in the Chemotherapeutic Treatment of Advanced Bladder Cancer

  • A Yagoda


The introduction of cisplatin in 1976 (35) in the treatment of patients with transitional cell carcinoma of the urothelial tract, i.e. renal pelvis, ureter, bladder, urethra and prostatic ducts, has led to a systematic evaluation of chemotherapeutic agents for advanced bladder cancer. Disease-orientated phase II trials, some utilizing strict patient selection and response criteria, have confirmed cisplatin’s antitumor activity — 35% (27, 10, 39) and recently phase III prospectively randomized disease-orientated studies have been instituted. This paper will outline presently available data and discuss two recently completed trials at Memorial Sloan-Kettering Cancer Center which utilize methotrexate (38, 17) and vinblastine (1), each used singly.


Bladder Cancer Radical Cystectomy Transitional Cell Carcinoma Chemotherapeutic Treatment Urinary Bladder Cancer 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    M. Blumenreich, A. Yagoda, R.C. Watson and B. Needles, Phase II Trial of Vinblastine Sulfate in Bladder Cancer, Amer. Soc. Clin. Oncol. Abstr. (1981), in press.Google Scholar
  2. 2.
    R.J. Cross, R.W. Glashan, C.S. Humphrey, M.R.G. Robinson, P.H. Smith and R.E. Williams, Treatment of Advanced Bladder Cancer with Adriamycin and 5 Fluorouracil, Brit. J. Urol. 48: 609 (1976).PubMedCrossRefGoogle Scholar
  3. 3.
    EORTC, The Treatment of Advanced Carcinoma of the Bladder with a Combination of Adriamycin and 5 Fluorouracil, Eur. Urol. 3: 276 (1977).Google Scholar
  4. 4.
    R. Gagliano, Adriamycin vs. Adriamycin plus Cisplatinum in Transitional Cell Bladder Carcinoma, Proc. Amer. Assoc. Cancer Res. 21: 347 (1980).Google Scholar
  5. 5.
    N.M. Gad-el-Mawla and J.L. Ziegler, Phase II Trial of Bleomycin in Bilharzial Bladder Cancer, Cancer Treat. Rep. 62: 1109 (1978a).Google Scholar
  6. 6.
    N.M. Gad-el-Mawla, R. Hamza, J. Cairns et al, Phase II Trial of Methotrexate in Carcinoma of the Bilharzial Bladder, Cancer Treat. Rep. 62: 1075 (1978b).Google Scholar
  7. 7.
    N.M. Gad-el-Mawla, F.M. Muggia, M.R. Hamza et al, Chemotherapeutic Management of Carcinoma of the Bilharzial Bladder: A Phase II Trial with Hexamethylmelamine and VM-26, Cancer Treat. Rep. 62: 993 (1978c).Google Scholar
  8. 8.
    N.M. Gad-el-Mawla, R. Hamza, E. Chevelen et al, Phase II Trial of Adriamycin in Carcinoma of the Bilharzial Bladder, Cancer Treat. Rep. 63: 227 (1979).PubMedGoogle Scholar
  9. 9.
    R.R. Hall, H.J.G. Bloom, J.E. Freeman et al, Methotrexate Treatment for Advanced Bladder Cancer, Brit. J. Urol. 46: 431 (1974).PubMedCrossRefGoogle Scholar
  10. 10.
    H. Herr, Diamminedichloride Platinum II in the Treatment of Advanced Bladder Cancer, J. Urol. 123: 953 (1980).Google Scholar
  11. 11.
    S.B. Martinos and M. Al-Sarraf, Phase II Study of 5-Fluorouracil and Adriamycin in Transitional Cell Carcinoma of the Urinary Tract, Cancer Treat. Rep. 64: 161 (1980).Google Scholar
  12. 12.
    J.E. Montie, W.F. Whitmore, H.M. Grabstald and A. Yagoda, Management of Patients with Locally Unresectable Carcinoma of the Bladder, (in preparation).Google Scholar
  13. 13.
    C.G. Moertel and J.A. Hanley, The Effect of Measuring Error on the Results of Therapeutic Trials in Advanced Cancer, Cancer 38: 388 (1976).PubMedCrossRefGoogle Scholar
  14. 14.
    A.S. Narayana, S.A. Leoning and D.A. Culp, Chemotherapy for Advanced Carcinoma of the Bladder, Proc. Amer. Urol. Assoc. 75th Annual Meeting, 122: 104 (1980).Google Scholar
  15. 15.
    R.B. Natale, A. Yagoda and D. Molander, In Vitro and In Vivo Sensitivity of Human Bladder Carcinoma: Correlation with Phase II Trials of AMSA, PALA and Methotrexate, Proc. Amer. Assoc. Cancer Res. 21: 297 (1980a).Google Scholar
  16. 16.
    R.B. Natale, A. Yagoda, R.C. Watson et al, Phase II Trial of Neocarcinostatin in Patients with Prostatic and Bladder Cancer Cancer, 45: 2836 (1980b).CrossRefGoogle Scholar
  17. 17.
    R.B. Natale, A. Yagoda, R.C. Watson et al, Methotrexate: An Active Drug in Bladder Cancer, Cancer (in press).Google Scholar
  18. 18.
    N.I. Nissen, T.F. Pajak, L.A. Leone et al, Clinical Trial of VP 16-213 (NSC 14150) i.v. Twice Weekly in Advanced Neoplastic Disease, Cancer 45: 232 (1980).PubMedCrossRefGoogle Scholar
  19. 19.
    R.M. O’Bryan, L.H. Baker, J.E. Gottleib et al, Dose Response Evaluation of Adriamycin in Human Neoplasia, Cancer 39: 1940 (1977).PubMedCrossRefGoogle Scholar
  20. 20.
    R.T.C. Oliver, The Place of Chemotherapy in the Treatment of Patients with Invasive Carcinoma of the Bladder, in “Bladder Tumors and Other Topics in Urological Oncology”, M. Pavone-Macaluso, P.H. Smith, F. Edsmyr, eds. Plenum Press, New York, pp 381–385 (1980).Google Scholar
  21. 21.
    M. Pavone-Hacaluso and EORTC Genitourinary Tract Cooperative Group A, Single Drug Chemotherapy of Bladder Cancer with Adriamycin, VM-26, or Bleomycin. A Phase II Multicentric Cooperative Study, Eur. Urol. 2: 138 (1976).Google Scholar
  22. 22.
    L.H. Rodriguez, D.E. Johnson, P.Y. Holoye et al, Combination VM-26 and Adriamycin for Metastatic Transitional Cell Carcinoma, Cancer Treat. Rep. 61: 87 (1977).PubMedGoogle Scholar
  23. 23.
    S. Sakamoto, J. Ogata, K. Ikegami et al, Chemotherapy for Bladder Cancer with Neocarcinostatin, Eur. J. Cancer 22: 103 (1980).Google Scholar
  24. 24.
    M.L. Samuels, CISCA Combination Chemotherapy in “2nd Annual Conference on Cancer of the Genitourinary Tract”, D.E. Johnson, M.L. Samuels, eds., Raven Press, New York, pp 97–106 (1979).Google Scholar
  25. 25.
    M.L. Samuels, C. Logothetis, A. Trindade et al, Cytoxan, Adriamycin and Cisplatinum (CISCA) in Metastatic Bladder Cancer, Proc. Amer. Assoc. Cancer Res. 21: 137 (1980).Google Scholar
  26. 26.
    J.A. Smith and W.F. Whitmore, Regional Lymph Node Metastasis from Bladder Cancer, J. Urol. (in press).Google Scholar
  27. 27.
    M.S. Soloway, Cis-diamminedichloroplatinum (II) (DDP) in Advanced Bladder Cancer, J. Urol. 120: 716 (1978).PubMedGoogle Scholar
  28. 28.
    M.S. Soloway and W.M. Murphy, Experimental Chemotherapy of Bladder Cancer — Systemic and Intravesical, Sem. Oncol. 6: 168 (1979).Google Scholar
  29. 29.
    J.J. Sternberg, R.B. Bracken, P.B. Handel et al, Combination Chemotherapy (CISCA) for Advanced Urinary Tract Carcinoma. A Preliminary Report, JAMA 238: 2282 (1977)PubMedCrossRefGoogle Scholar
  30. 30.
    A.G. Turner, W.F. Hendry, G.B. Williams et al, The Treatment of Advanced Bladder Cancer with Methotrexate, Brit. J. Urol. 49: 673 (1977).PubMedCrossRefGoogle Scholar
  31. 31.
    S.D. Williams, L.H. Einhorn, J.P. Donohue, Cis-platinum Combina¬tion Chemotherapy of Bladder Cancer, Cancer Clin. Trials, Cancer Chemotherapy 2: 355 (1979).Google Scholar
  32. 32.
    A. Yagoda, Future Implications of Phase II Chemotherapy Trials in ninety-five Patients with Measurable Advanced Bladder Cancer, Cancer Res. 37: 2275 (1977).Google Scholar
  33. 33.
    A. Yagoda, R.C. Watson, H. Grabstald, W.E. Barzell and W.F. Whitmore, Adriamycin and Cyclophosphamide in Advanced Bladder Cancer, Cancer Treat. Rep. 61: 31 (1977b).Google Scholar
  34. 34.
    A. Yagoda, Chemotherapy of Metastatic Bladder Cancer, Cancer 45: 1879 (1980).PubMedGoogle Scholar
  35. 35.
    A. Yagoda, R.C. Watson, Gonzalez-Vitale et al, Cis-dichloro-diammineplatinum (II) in Advanced Bladder Cancer, Cancer Treat. Rep. 60: 917 (1976).PubMedGoogle Scholar
  36. 36.
    A. Yagoda, R.C. Watson, W.F. Whitmore et al, Adriamycin in Advanced Urinary Tract Cancer, Cancer 39: 279 (1977a).PubMedCrossRefGoogle Scholar
  37. 37.
    A. Yagoda, R.C. Watson, N. Kemeny et al, Diamminedichloride Platinum II and Cyclophosphamide in the Treatment of Advanced Urothelial Cancer, Cancer 41: 2121 (1978).PubMedCrossRefGoogle Scholar
  38. 38.
    A. Yagoda, R.C. Watson, W.F. Whitmore, Phase II Trial of Methotrexate in Urinary Bladder Cancer, Proc. Amer. Assoc. Cancer Res. 21: 427 (1980a).Google Scholar
  39. 39.
    A. Yagoda, R.C. Watson, R. Blumenreich et al, Phase II Trials in Urothelial Tumors with AMSA and PALA, Proc. Amer. Assoc. Cancer Res. 21: 427 (1980b).Google Scholar

Copyright information

© Plenum Press, New York 1982

Authors and Affiliations

  • A Yagoda
    • 1
  1. 1.Memorial Sloan-Kettering Cancer CenterNew YorkUSA

Personalised recommendations